RecruitingNot ApplicableNCT06095050

Embolization Treatment of Chronic Refractory Shoulder Tendinopathy

Efficacy of Lipiodol Embolization for Chronic Tendinopathy of the Rotator Cuff


Sponsor

Brigham and Women's Hospital

Enrollment

41 participants

Start Date

Jan 16, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a randomized controlled trial in which patients with moderate to severe shoulder pain (Visual Analog Scale (VAS) \> 40), in the setting of rotator cuff tendinopathy refractory to conservative treatment, will be enrolled. The primary aim of the study is to estimate the effect of transcatheter arterial embolization (TAE) with physical therapy (PT) vs PT alone on the change in shoulder pain at 12-month follow up. Scientific objectives also include an assessment of safety of the intervention, assessment of changes in Patient-Reported Outcomes Measurement Information System (PROMIS) Upper Extremity score, Shoulder Pain and Disability Index (SPADI) scores, MRI Tendinopathy Score between the TAE + PT and PT groups.


Eligibility

Min Age: 21 YearsMax Age: 80 Years

Inclusion Criteria4

  • Male, female, transgender female, transgender male, non-binary
  • Moderate to severe shoulder pain (VAS \> 40)
  • Pain refractory to at least 6 months of physician-directed conservative therapy (analgesics or injections or PT), including a minimum of 6 weeks of PT
  • Willing, able, and mentally competent to provide informed consent and to tolerate angiography and physical therapy

Exclusion Criteria12

  • History of peripheral arterial disease or peripheral artery disease symptoms including claudication, diminished or absent upper/lower extremity pulses, or known upper extremity arterial atherosclerosis or occlusion that would limit selective angiography
  • Known history of anaphylaxis to iodinated contrast agents or gadolinium based contrast
  • Acute kidney injury
  • Allergy to poppy seeds or lipiodol
  • Renal dysfunction as defined by serum creatinine \>1.6 dl/mg or eGFR \<60 obtained within 30 days of procedure.
  • Uncorrectable coagulopathy (platelet count \< 50,000, international normalized ratio \>1.8 within 30 days of procedure
  • Active systemic or local upper extremity infection
  • Patient pregnant, intending to become pregnant during the study.
  • Prior shoulder replacement surgery
  • Prior rotator cuff repair surgery
  • Previous history of complete full-thickness tear of the rotator cuff
  • Presence of non-MRI compatible devices (e.g., non-compatible cardiac pacemaker).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEEmbolization

Superselective arterial embolization of hyperemic vasculature in the symptomatic shoulder (utilizing the IDE approved device: Lipiodol) followed by structured physical therapy sessions.

OTHERPhysical Therapy

Subjects will participate in structured physical therapy consisting of 3 months of eccentric strength training. This twelve-week program will consist of 4 PT sessions at week 0, week 4, week 8, and week 12.


Locations(1)

Brigham and Women's Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06095050


Related Trials